Found 7 matching trials
Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial NA Clinical Trial Protocol
Primary Objective:
To evaluate the efficacy of th...
Show More Location
Jiangxi Provincial People's Hospital
Learn More & Join Trial
Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) PHASE2 This is an open label, multi-center, randomized control phase II trial, to ...
Show More Location
Multiple Locations
Learn More & Join Trial
Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. PHASE2 For unresectable and metastatic advanced biliary tract cancers (BTCs), gemc...
Show More Status
Active Not Recruiting
Location
Tianjin Medical University Cancer Institute and Hospital
Learn More & Join Trial
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer PHASE2 To evaluate the efficacy and safety of Sintilimab combined with apatinib an...
Show More Location
Affiliated Hospital of Qinghai University
Learn More & Join Trial
Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer PHASE2 This prospective, multi-center, open-label, phase II, randomized controlled...
Show More Status
Active Not Recruiting
Location
Tianjin Medical University Cancer Institute and Hospital
Learn More & Join Trial
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer PHASE2 This is a single arm, multi-center clinical trial. The goal of this clinica...
Show More Location
Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Learn More & Join Trial
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery PHASE2 Approximately 5% to 10% of gastric cancers have MSI-H/dMMR. According to th...
Show More Status
Active Not Recruiting
Learn More & Join Trial